Department of Pharmacology, College of Medicine, University of Jeddah, Jeddah, 45311, Saudi Arabia.
Pharmacol Rep. 2024 Oct;76(5):981-990. doi: 10.1007/s43440-024-00629-x. Epub 2024 Aug 2.
Glucagon-like peptide-1 (GLP-1) agonists play a crucial role in treating type 2 diabetes mellitus and obesity by providing glycemic control and aiding weight management. Despite their widespread use, concerns about serious adverse events have prompted extensive research. This review aims to describe the current understanding of serious adverse events associated with GLP-1 agonists. A comprehensive search of PubMed, Google Scholar and Embase databases was performed starting from 2010. Studies reporting evidence of an association between GLP-1 agonists and serious adverse events from 22 articles (5 case reports, 5 randomized controlled trials (RCTs), 9 real-world data cohort analyses, 2 meta-analyses and 1 systematic review and meta-analysis) were included and categorized by the type of adverse event. While some studies reported risks, including anaphylaxis, cardiovascular, gastrointestinal, psychiatric and thyroid-related events, others found no significant associations. The evidence remains mixed, necessitating further research to fully understand the safety profile of GLP-1 agonists and inform clinical practice.
胰高血糖素样肽-1（GLP-1）激动剂在治疗 2 型糖尿病和肥胖症方面发挥着重要作用，可实现血糖控制并有助于体重管理。尽管它们被广泛应用，但严重不良事件的担忧促使人们进行了广泛的研究。本综述旨在描述与 GLP-1 激动剂相关的严重不良事件的现有认识。从 2010 年开始，对 PubMed、Google Scholar 和 Embase 数据库进行了全面检索。纳入了 22 篇文章（5 篇病例报告、5 项随机对照试验（RCT）、9 项真实世界数据队列分析、2 项荟萃分析和 1 项系统评价和荟萃分析）报告 GLP-1 激动剂与严重不良事件之间存在关联证据的研究，并按不良事件的类型进行分类。虽然一些研究报告了风险，包括过敏反应、心血管、胃肠道、精神和甲状腺相关事件，但其他研究并未发现显著关联。证据仍然存在分歧，需要进一步研究以充分了解 GLP-1 激动剂的安全性概况并为临床实践提供信息。
